ExeGi Pharma Positive Topline Results in EXE-346 PROF Phase 1b Study
PROF study demonstrates safety of EXE-346 drug product in pouch anastomosis patients at 3,000 billion live probiotic consumption per day for four weeksExcessive bowel movement (BM) frequency was reduced at